By SPC News Staff
The FDA approved ranibizumab-nuna (Byooviz, Samsung Bioepis/Biogen) as the first biosimilar to ranibizumab injection (Lucentis, Genentech) to treat several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.
Ranibizumab-nuna is also approved to treat macular edema following retinal vein occlusion and myopic choroidal neovascularization (mCNV), a